Autonomix Medical, Inc. Granted New European Patent for Proprietary Catheter-Based Technology
Rhea-AI Summary
Autonomix Medical (NASDAQ: AMIX) has been granted European Patent No. 3,226,792 for its catheter-based technology in neuromodulation. The patent covers methods and systems for nerve monitoring and surgical procedures related to regulating prostate and tumor growth.
The technology's applications include sensing, ablating, and verifying neurological traffic to the prostate and lower urinary tract (LUT) organs, with potential to treat conditions like chronic prostatitis, hypogonadism, nocturia, and erectile dysfunction. The company's patent portfolio now includes over 80 issued patents and 40 pending applications.
While primarily focused on developing treatments for pancreatic cancer pain by targeting the celiac plexus, Autonomix plans to submit an IDE and begin U.S. clinical trials in 2025 to commercialize their Sensing and RF Ablation System.
Positive
- Secured new European patent strengthening intellectual property portfolio
- Extensive patent protection with 80+ issued patents and 40 pending applications
- Technology has broad applications across multiple medical conditions
- Clear commercialization timeline with clinical trials planned for 2025
Negative
- No immediate revenue generation as product still in development phase
- Clinical trials and regulatory approval still pending
- Commercialization timeline extends into 2025 and beyond
Insights
Autonomix's new European patent (No. 3,226,792) represents a strategic expansion of their intellectual property portfolio in the neuromodulation space. The patent specifically covers systems and methods for sensing, ablating, and verifying neurological traffic to regulate prostate and tumor growth—effectively broadening their technology platform beyond their current focus on pancreatic pain.
This patent approval provides dual value: immediate protection of their proprietary catheter-based technology in the European market and longer-term optionality for expanding into additional therapeutic areas. For context, this brings their global patent portfolio to over 80 issued patents with 40 more pending applications.
The technical scope of this patent is particularly noteworthy as it encompasses applications for lower urinary tract diseases sharing prostatic plexus physiology, including chronic prostatitis, hypogonadism, nocturia, and erectile dysfunction. This breadth suggests Autonomix has secured protection for multiple potential commercial pathways while maintaining their near-term focus on pancreatic cancer pain.
For medical device companies, especially those with market capitalizations under $5 million, securing robust patent protection in major markets is essential for future commercialization and partnership opportunities. European patent protection specifically opens avenues for regional partnerships that might otherwise remain closed.
While this patent doesn't alter their immediate clinical timeline—they still plan to submit an IDE and commence U.S. clinical trials in 2025—it does strengthen their competitive positioning by establishing technological barriers to entry and potentially opening additional revenue streams if they choose to pursue these alternative applications in the future.
New patent underscores breadth of application and expansion opportunities for Company’s catheter-based technology
Continued progress with growing global patent portfolio to over 80 issued patents and 40 pending patent applications
THE WOODLANDS, TX, April 16, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that European Patent Office (EPO) has granted Patent No. 3,226,792 (the ‘792) titled, “Systems And Methods For Regulating Organ and/or Tumor Growth Rates, Function, and/or Development.” The granted ‘792 patent relates to the field of neuromodulation and covers a range of methods and systems used in nerve and receptor monitoring, electrophysiological monitoring, and surgical procedures related to the systems and mechanisms that regulate prostate and tumor growth.
“With the potential to address a wide range of conditions in which nerve activity plays a central role, we remain committed to strengthening our patent portfolio to support future applications and expansion opportunities. This European patent further validates the broad applicability of our technology across multiple conditions and anatomical targets. While our focus is on advancing development to reduce pancreatic cancer pain by targeting the celiac plexus, we believe our novel approach has the potential to address a broad array of peripheral nerve bundles associated with pain,” commented Brad Hauser, CEO of Autonomix.
In particular, the methods and systems covered in the ‘792 patent may be used to sense, ablate and verify neurological traffic to and from the prostate and organs of the lower urinary tract (LUT) in order to slow, halt and/or reverse the growth of a prostate gland or a prostate tumor. Beyond prostate-related treatments, these systems and methods have potential applications in addressing various LUT diseases that share physiology of the prostatic plexus, including chronic prostatitis, hypogonadism, nocturia, and erectile dysfunction, by modulating neural activity and hormonal secretions of related organs.
The Company is currently advancing its plans to submit an IDE and commence U.S. clinical trials in 2025 to support a labeling indication to commercialize the Autonomix Sensing and RF Ablation System in the U.S. as a treatment for pancreatic cancer pain.
For more information about the Company’s technology, please visit autonomix.com.
About Autonomix Medical, Inc.
Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.
We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.
For more information, visit autonomix.com and connect with the Company on X, LinkedIn, Instagram and Facebook.
Forward Looking Statements
Some of the statements in this release are “forward-looking statements,” which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the potential of the technology to treat cancerous tumors and the pain associated with pancreatic cancer. Such forward-looking statements can be identified by the use of words such as “should,” “might,” “may,” “intends,” “anticipates,” “believes,” “estimates,” “projects,” “forecasts,” “expects,” “plans,” and “proposes.”
Although Autonomix believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading “Risk Factors” and elsewhere in the Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on May 31, 2024. Forward-looking statements speak only as of the date of the document in which they are contained and Autonomix does not undertake any duty to update any forward-looking statements except as may be required by law.
Investor and Media Contact
JTC Team, LLC
Jenene Thomas
908.824.0775
autonomix@jtcir.com
FAQ
What is the scope of Autonomix Medical's (AMIX) new European patent?
What medical conditions can AMIX's patented technology potentially treat?
When does Autonomix Medical (AMIX) plan to begin clinical trials for pancreatic cancer pain treatment?
How many patents does Autonomix Medical (AMIX) currently hold?
